EUVIMEDOntdek EUVIMED
Open access · CC BY-NC 4.0

Safety and Efficacy of Long‐Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial

Amit Saxena iD, Ellen M Ginzler, Keisha Gibson, Bancha Satirapoj, Adolfina Elizabeth Zuta Santillán, Olena Levchenko, Sandra Navarra, Tatsuya Atsumi, Shinsuke Yasuda iD, Nilmo Noel Chavez-Perez, Cristina Arriens iD, Samir V Parikh iD and 6 more

Arthritis & Rheumatology · 2024-01 · 76 (1) · 59-67

DOI: 10.1002/art.42657 ↗

At a glance

Journal article in Arthritis & Rheumatology, published online on 2023-09-15. Written by Amit Saxena and 17 co-authors. Institution: Division of Rheumatology, New York University School of Medicine, New York, New York. Major MEDLINE topics: Lupus Nephritis. Cited 129 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Aurinia Pharmaceuticals Inc..

SamenvattingSubjectsBibliografische gegevensCiteRelated studies

Abstract (original language)

Objective

AURORA 2 evaluated the long‐term safety, tolerability, and efficacy of voclosporin compared to placebo in patients with lupus nephritis (LN) receiving an additional two years of treatment following completion of the one‐year AURORA 1 study.

Methods

Enrolled patients continued their double‐blinded treatment of voclosporin or placebo randomly assigned in AURORA 1, in combination with mycophenolate mofetil and low‐dose glucocorticoids. The primary objective was safety assessed with adverse events (AEs) and biochemical and hematological assessments. Efficacy was measured by renal response.

Results

A total of 216 patients enrolled in AURORA 2. Treatment was well tolerated with 86.1% completing the study and no unexpected safety signals. AEs occurred in 86% and 80% of patients in the voclosporin and control groups, respectively, with an AE profile similar to that seen in AURORA 1, albeit with reduced frequency. Investigator reported AEs of both glomerular filtration rate (GFR) decrease and hypertension occurred more frequently in the voclosporin than the control group (10.3% vs 5.0%, and 8.6% vs 7.0%, respectively). Mean corrected estimated GFR (eGFR) was within the normal range and stable in both treatment groups. eGFR slope over the two‐year period was −0.2 mL/min/1.73 m 2 (95% confidence interval [CI] −3.0 to 2.7) in the voclosporin group and −5.4 mL/min/1.73 m 2 (95% CI −8.4 to −2.3) in the control group. Improved proteinuria persisted across three years of treatment, leading to more frequent complete renal responses in patients treated with voclosporin (50.9% vs 39.0%; odds ratio 1.74; 95% CI 1.00–3.03).

Conclusion

Data demonstrate the safety and efficacy of long‐term voclosporin treatment over three years of follow‐up in patients with LN. image

Subjects

MeSH terms (MEDLINE)

Lupus NephritisHumansImmunosuppressive AgentsCyclosporineMycophenolic AcidTreatment Outcome

Substances

voclosporinImmunosuppressive AgentsCyclosporineMycophenolic Acid

Authors and institutions

  • Division of Rheumatology, New York University School of Medicine, New York, New York.
  • Department of Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York.
  • Department of Medicine, UNC Kidney Center, Chapel Hill, North Carolina.
  • Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand.
  • Instituto de Ginecología y Reproducción, Lima, Peru.
  • Odessa Regional Clinical Hospital, Oblast, Ukraine.

ORCID profiles: Amit Saxena, Shinsuke Yasuda, Cristina Arriens, Samir V Parikh, Vanessa Birardi, Simrat Randhawa

Funding

  • Aurinia Pharmaceuticals Inc.

Cite

APA

Saxena, A., Ginzler, E. M., Gibson, K., Satirapoj, B., Santillán, A. E. Z., Levchenko, O., Navarra, S., Atsumi, T., Yasuda, S., Chavez-Perez, N. N., Arriens, C., Parikh, S. V., Caster, D. J., Birardi, V., Randhawa, S., Lisk, L., Huizinga, R. B., & Teng, Y. K. O. (2024). Safety and Efficacy of Long‐Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial. Arthritis & Rheumatology, 76(1), 59-67. https://doi.org/10.1002/art.42657

Vancouver

Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillán AEZ, Levchenko O, et al. Safety and Efficacy of Long‐Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial. Arthritis & Rheumatology. 2024;76(1):59-67. doi:10.1002/art.42657

BibTeX
@article{Saxena2024,
  author = {Saxena, Amit and Ginzler, Ellen M and Gibson, Keisha and Satirapoj, Bancha and Santillán, Adolfina Elizabeth Zuta and Levchenko, Olena and Navarra, Sandra and Atsumi, Tatsuya and Yasuda, Shinsuke and Chavez-Perez, Nilmo Noel and Arriens, Cristina and Parikh, Samir V and Caster, Dawn J and Birardi, Vanessa and Randhawa, Simrat and Lisk, Laura and Huizinga, Robert B and Teng, Y K Onno},
  title = {Safety and Efficacy of Long‐Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  volume = {76},
  number = {1},
  pages = {59--67},
  doi = {10.1002/art.42657}
}
Start for free →